An inhibitor of Bcl-2 family proteins induces regression of solid tumoursTilman Oltersdorf, Saul H. Rosenberg, Jacqueline M. O’Connor et al.|Nature|2005Cited by 3.4k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Joel D. Leverson et al.|Nature Medicine|2013Cited by 3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorChristin Tse, Steven W. Elmore, Alexander R. Shoemaker et al.|Cancer Research|2008Cited by 2k
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Darren C. Phillips et al.|Science Translational Medicine|2015Cited by 541
Discovery of a Potent and Selective BCL-X <sub>L</sub> Inhibitor with <i>in Vivo</i> ActivityZhi‐Fu Tao, Andrew J. Souers, Lisa Hasvold et al.|ACS Medicinal Chemistry Letters|2014Cited by 331